Tullahoma News

Tullahoma News is a local news source that provides coverage on a variety of topics, including business, health, and local events. Our mission is to provide accurate and timely information to our readers.

60%

The Daily's Verdict

This news site has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

0%

Examples:

  • In the article titled 'New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes', the title promises new insights on Hyperkalemia and safety of Kerendia for patients with Chronic Kidney Disease associated with Type 2 Diabetes, but the body of the article does not contain any information related to this.

Recent Articles

  • Investigation Underway into Unauthorized Release of Covenant School Shooter's Writings

    Broke On: Monday, 06 November 2023 The city of Nashville is investigating the unauthorized release of writings allegedly belonging to the Covenant School shooter. The Metro Nashville Police Department has confirmed that the leaked images were not from their crime scene. Parents of students at Covenant School have expressed outrage over the leaked writings, suspecting a member of the Metro Nashville Police Department is responsible for the leak. The writings have been the subject of an ongoing court case, with right-wing activists and media figures pushing for their public release.
  • Semaglutide and Sotagliflozin Show Promising Results for Type 2 Diabetes Patients

    Broke On: Friday, 03 November 2023 The majority of patients did not experience worsening of their diabetic retinopathy (DR) after initiating semaglutide (Ozempic) to treat their type 2 diabetes (T2D). Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with type 2 diabetes and chronic kidney disease. Over a median follow-up of 16 months, sotagliflozin reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%.